The new era in the treatment of rheumatoid arthritis.
Putterman
Chaim
C
Division of Rheumatology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, New York, USA.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D015536:Down-Regulation / Q000187:drug effects; D004359:Drug Therapy, Combination; D020022:Genetic Predisposition to Disease; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D017472:Receptors, Interleukin-1; D014409:Tumor Necrosis Factor-alpha